The US department of justice (DoJ) has said there are evidences which suggest that Ranbaxy used active pharmaceutical ingredients (API) from unapproved sources, blended unapproved API with approved API, and used less-than-approved API at its Paonta Sahib (Himachal Pradesh) plant in its drugs. Using this, the company has sold subpotent, super potent or adulterated medicines in the US market.
APIs are raw materials used for manufacturing medicine.
The DoJ also said contrary to the stipulation of manufacturers using approved sites, evidence suggests that Ranbaxy manufactures products at other plants and obtains API from unapproved sources.
No comments:
Post a Comment